<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">GOSERELIN ACETATE</span><br/>(gos-er'e-lin)<br/><span class="topboxtradename">Zoladex<br/></span><b>Classifications:</b> <span class="classification"> hormone and synthetic substitute</span>; <span class="classification">gonadotropin-releasing hormone analog</span><br/><b>Prototype: </b>Leuprolide<br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>3.6 mg, 10.8 mg SC implant</p>
<h1><a name="action">Actions</a></h1>
<p>A synthetic form of luteinizing hormone-releasing hormone (LHRH or GnRH) that inhibits pituitary gonadotropin secretion.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>With chronic administration, serum testosterone levels fall into the range normally seen with surgically castrated men.</p>
<h1><a name="uses">Uses</a></h1>
<p>Prostate cancer, breast cancer. Endometrial thinning agent prior to endometrial ablation for dysfunctional uterine bleeding.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Endometriosis, uterine leiomyomas.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Pregnancy (category X); lactation; known hypersensitivity to a LHRH; endometriosis or endometrial thinning; hypercalcemia.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Urinary tract obstruction and children; family history of osteoporosis; concurrent use with anticonvulsants or corticosteroids.
         Safety and efficacy in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Prostate Cancer, Breast Cancer, Endometriosis, Uterine Leiomyomas</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> 3.6 mg once q28d. 10.8 mg depot q12 wk<br/><br/><span class="indicationtitle">Endometrial Thinning Prior to Endometrial Ablation</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> 3.6 mg once q28d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li>Follow manufacturer's directions exactly for implanting the drug SC in the upper abdominal wall.</li>
<li>Store at room temperature not to exceed 25° C (77° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, tumor flare. <span class="typehead">Endocrine:</span> Gynecomastia, breast swelling and tenderness, <span class="speceff-common">postmenopausal symptoms</span> (<span class="speceff-common">hot flashes</span>, vaginal dryness). <span class="typehead">GI:</span> Nausea. <span class="typehead">Urogenital:</span> Vaginal spotting, breakthrough bleeding, decreased libido, <span class="speceff-common">impotence.</span> <span class="typehead">Musculoskeletal:</span> Bone pain, bone loss. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Increased levels of <span class="alt">alkaline phosphatase</span> and <span class="alt">estradiol</span> in the first 18 d; initial increase then decrease in <span class="alt">FSH,</span> <span class="alt">LH,</span> and <span class="alt">testosterone.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed following SC administration. <span class="typehead">Duration:</span> 29 d. <span class="typehead">Elimination:</span> Excreted by kidneys. <span class="typehead">Half-Life:</span> 4.9 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor carefully during the first month of therapy for S&amp;S of spinal cord compression or ureteral obstruction in patients
            with prostate cancer. Report immediately to physician.
         </li>
<li>Anticipate a transient worsening of symptoms (e.g., bone pain) during the first weeks of therapy in patients with prostate
            cancer.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li> 							Note: Sexual dysfunction in men and hot flashes may accompany drug use. 						</li>
<li>Notify physician immediately of symptoms of spinal cord compression or urinary obstruction.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>